Cost-Effectiveness of Irbesartan 300 mg Given Early Versus Late in Patients with Hypertension and a History of Type 2 Diabetes and Renal Disease: A Canadian Perspective

Clinical Therapeutics

Volumn 29, Issue 7, 2007, Pages 1508-1523

  Coyle, Douglas ^a   Rodby, Roger ^b   Soroka, Steven ^c   Levin, Adeera ^d   Muirhead, Norman ^e   de Cotret, Paul René ^f   Chen, Roland ^g   Palmer, Andrew ^h  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e London Health Science Center   (Canada)

^f UNIVERSITÉ LAVAL   (Canada)

^g BRISTOL MYERS SQUIBB   (United States)

^h IQVIA   (United States)

Author keywords

cost effectiveness; diabetic nephropathy; hypertension; irbesartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CREATININE; INSULIN; IRBESARTAN;

ANAMNESIS; ARTICLE; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MARKUP LANGUAGE; MICROALBUMINURIA; MONTE CARLO METHOD; PATIENT CARE; SOCIAL CARE; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIPHENYL COMPOUNDS; CANADA; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPERTENSION; MARKOV CHAINS; MODELS, ECONOMETRIC; NATIONAL HEALTH PROGRAMS; RENAL DIALYSIS; TETRAZOLES; TIME FACTORS;

EID: 34548384965     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.07.029     Document Type: Article

References (32)

1. Go A., Chertow G., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
2. Health Canada. Diabetes in Canada: National statistics and opportunities For improved surveillance, prevention and control (1999), Minister of Public Works and Government Services Canada, Ottawa, Ontario, Canada
3. US Renal Data System. USRDS 1999 Annual Data Report (1999), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md
4. Lippert J., Ritz E., Schwarzbeck A., and Schneider P. The rising tide of endstage renal Failure From diabetic nephropathy type II-an epidemiological analysis. Nephrol Dial Transplant. 10 (1995) 462-467
5. Brown J., Pedula K., and Bakst A. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med. 159 (1999) 1873-1880
6. Lloyd A., Sawyer W., and Hopkinson P. Impact of long-term complications on quality of-life in patientswith type 2 diabetes not using insulin. Value Health 4 (2001) 392-400
7. Kobrin S. Diabetic nephropathy. Dis Mon. 44 (1998) 214-234
8. Arauz-Pacheco C., Parrott M., and Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 25 (2002) 134-147
9. Haffner S. Management ofdyslipidemia in adults with diabetes. Diabetes Care 21 (1998) 160-178
10. American Diabetes Association. Facts & Figures. http://www.diabetes.org Available at: Accessed July 10, 2007
11. Lewis E., Hunsicker L., Clarke W., et al., Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 345 (2001) 851-860
12. Parving H., Lehnert H., Brochner-Mortensen J., et al. For the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
13. Briggs A., and Sculpher M. An introduction to Markov modeling for economic evaluation. PharmacoEconomics 13 (1998) 397-409
14. Life Tables, Canada and Provinces. 1990-1992. 84-537 Occasional (1995), Statistics Canada, Ottawa, Ontario, Canada
15. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
16. Manns B., Tonelli M., Shrive F., et al. Sevelamer in patients with end-stage renal disease: A systematic review and economic evaluation. Technology Report no. 71 (2006), Canadian Agency for Drugs and Technologies in Health, Ottawa, Ontario, Canada
17. Ontario Drug Formulary 2004. Ontario, Canada: Ontario Ministry of Health and Long-Term Care; 2004.
18. Coyle D., and Rodby R. Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. Can J Cardiol 20 (2004) 71-79
19. Chun B., Coyle D., Berthelot J., et al. Estimating the costs of coronary heart disease in Manitoba. Proceedings of the American Statistical Association Joint Annual Meeting (May 1997) Chicago, III
20. Briggs A., Goeree R., Blackhouse G., and O'Brien B. Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastroesophogeal reflux disease. Med Decis Making 22 (2002) 290-308
21. The Canadian Coordinating Office for Health Technology Assessment. Guidelines for the economic evaluation of pharmaceuticals (1997), CCOHTA, Ottawa, Ontario, Canada
22. Briggs A., Sculpher M., and Buxton M. Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis. Health Econ. 3 (1994) 95-104
23. Doubilet P., Begg C., Weinstein M., et al. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making. 5 (1985) 157-177
24. Spiegelhalter D., Myles J., Jones D., and Abrams K. Bayesian methods in health technology assessment: A review. Health Technol Assess 4 (2000) 1-130
25. Fenwick E., Claxton K., and Sculpher M. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ. 10 (2001) 779-787
26. Lothgren M., and Zethraeus N. Definition interpretation and calculation of cost-effectiveness acceptability curves. Health Econ. 9 (2000) 623-630
27. Burgess E., Carides G., and Gerth W. et al. for the Canadian Hypertension Society. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective. Can J Cardiol. 20 (2004) 613-618
28. Palmer A., Annemans L., Roze S., et al. Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and micro-albuminuria. Kidney Int Suppl 93 (2005) S52-S54
29. Palmer A., Annemans L., Roze S., et al. Cost-effectiveness of early irbesartan treatment versus control (standard anti-hypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydro-pyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 27 (2004) 1897-1903
30. CDC Diabetes Cost-Effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287 (2002) 2542-2551
31. O'Brien B. Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials?. Med Care 34 Suppl 12 (1996) DS99-DS108
32. The Canadian Diabetes Association 2003. Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. http://www.diabetes.ca/cpg2003/downloads/nephropathy.pdf Available at: Accessed August 10, 2005